X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Fruzaqla (fruquintinib) is a selective oral VEGFR inhibitor it plays a pivotal role in blocking tumor angiogenesis. It is being investigated in combination with sintilimab (PD-1 inhibitor) for the treatment of advanced endometrial cancer.
Lead Product(s): Fruquintinib,Sintilimab
Therapeutic Area: Oncology Product Name: Fruzaqla
Highest Development Status: Phase IIProduct Type: Small molecule
Recipient: Hutchmed
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 01, 2024
Details:
IBI310 (anti-CTLA-4 monoclonal antibody) in combination with sintilimab (PD-1 inhibitor) is being evaluated for the treatment of MSI-H/dMMR Resectable Colon Cancer.
Lead Product(s): Ipilimumab,Sintilimab
Therapeutic Area: Oncology Product Name: IBI310
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 26, 2024
Details:
IBI302 (efdamrofusp alfa) is a recombinant human VEGFR-Fc-Human CR1 fusion protein injection. It is being evaluated for the treatment of patients with neovascular age-related macular degeneration.
Lead Product(s): Efdamrofusp alfa
Therapeutic Area: Ophthalmology Product Name: IBI302
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 18, 2024
Details:
AB-106 (taletrectinib) is a next-generation ROS1 tyrosine kinase inhibitor (TKI), which is being evaluated for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC).
Lead Product(s): Taletrectinib
Therapeutic Area: Oncology Product Name: AB-106
Highest Development Status: Phase IIProduct Type: Small molecule
Recipient: AnHeart Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 04, 2024
Details:
IBI3002 is a global first-in-class bispecific antibody targeting Interleukin 4 receptor α (IL-4Rα) and thymic stromal lymphopoietin (TSLP). It is being evaluated for the treatment of mild to moderate asthma.
Lead Product(s): IBI3002
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: IBI3002
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 29, 2024
Details:
IBI311 is a recombinant anti-insulin-like growth factor 1 receptor (IGF-1R) antibody. It is currently being evaluated for the treatment of thyroid eye disease.
Lead Product(s): IBI311
Therapeutic Area: Immunology Product Name: IBI311
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 19, 2024
Details:
IBI362 (mazdutide) is a glucagon-like peptide-1 receptor GLP-1R/GCGR dual agonist. It is being evaluated in phase 3 clinical trials for chronic weight management.
Lead Product(s): Mazdutide
Therapeutic Area: Nutrition and Weight Loss Product Name: IBI362
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 07, 2024
Details:
IBI362 (mazdutide) is a GLP-1R and GCGR dual agonist. It is under phase 3 clinical development for the treatment of adults with overweight or obesity.
Lead Product(s): Mazdutide
Therapeutic Area: Nutrition and Weight Loss Product Name: IBI362
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Eli Lilly
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 08, 2024
Details:
IBI362 (mazdutide) is a glucagon-like peptide 1 receptor (GLP-1R) and glucagon receptor (GCGR) dual agonist, which is under phase 3 clinical development for the treatment of obesity.
Lead Product(s): Mazdutide
Therapeutic Area: Nutrition and Weight Loss Product Name: IBI362
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Eli Lilly
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 01, 2024
Details:
Through collaboration, Xuanzhu Biopharma will conduct a Phase 1b clinical study to evaluate the anti-tumor activity and safety of the combination therapy of sintilimab with KM-501 in Chinese patients with advanced solid tumors.
Lead Product(s): KM-501,Sintilimab
Therapeutic Area: Oncology Product Name: KM-501
Highest Development Status: PreclinicalProduct Type: Large molecule
Recipient: Xuanzhu Biopharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration December 27, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
